This case demonstrates the multifaceted complexity of current-day NSCLC management, with evidence suggesting that high PD-L1 does not dictate response to immunotherapy and, in fact, is associated with aggressive tumor growth. This evidence concerns the gene CD274 and non-small cell lung carcinoma.